← back to search

Nader Khalidi

University of Amsterdam · CA
Area of research
Pulmonary and Respiratory Medicine · Rheumatology
Research interest
Research interests include Vasculitis and related conditions, Systemic Sclerosis and Related Diseases, Otitis Media and Relapsing Polychondritis, and Inflammatory Myopathies and Dermatomyositis.
h-index
51
citations
7,867
works
227
NIH funding
primary concept
Medicine
email

Recent publications

Benralizumab reduces sputum ANCA in patients with eosinophilic granulomatosis with polyangiitis.
2026cited by 0position: contributordoi
Altered peripheral γδT cell profiles with increased IL-17A secretion in patients with eosinophilic granulomatosis with polyangiitis
Canadian Journal of Respiratory, Critical Care, and Sleep Medicine 2026cited by 0position: contributordoi
A Phase 3 Trial of Upadacitinib for Giant-Cell Arteritis
New England Journal of Medicine 2025cited by 70position: middledoi
A Randomized, Double‐Blind, Placebo‐Controlled Trial of Abatacept for the Treatment of Relapsing, Nonsevere Granulomatosis With Polyangiitis
Arthritis & Rheumatology 2025cited by 8position: middledoi
Vessel wall MRI in giant cell arteritis: standardized protocol and scoring approach developed by an international working group.
2025cited by 5position: contributordoi
Intracranial GCA: a comprehensive systematic review.
2025cited by 3position: contributordoi
Multivariable Models to Predict a Diagnosis of Giant Cell Arteritis: Systematic Review and Metaanalysis.
2025cited by 1position: contributordoi
A glossary of signs and symptoms of giant cell arteritis
Annals of the Rheumatic Diseases 2025cited by 1position: contributordoi
POS0082 EXPLORING THE GENETIC BASIS OF CLINICAL HETEROGENEITY IN GIANT CELL ARTERITIS
Annals of the Rheumatic Diseases 2025cited by 0position: middledoi
Assessment of Giant Cell Arteritis-Associated Visual Outcomes at a Tertiary Hospital in Ontario, Canada.
2025cited by 0position: contributordoi
Immune checkpoint inhibitor associated vasculitis and polymyalgia rheumatica: a case series and systematic review.
2025cited by 0position: contributordoi
Clinical Characteristics and Outcomes of Polyarteritis Nodosa: An International Study
Arthritis & Rheumatology 2024cited by 25position: middledoi
Risk loci involved in giant cell arteritis susceptibility: a genome-wide association study
The Lancet Rheumatology 2024cited by 19position: middledoi
Clinical Characteristics and Outcomes of Polyarteritis Nodosa: An International Study.
2024cited by 18position: contributordoi
Assessment of damage in Takayasu’s arteritis
Lara D. Veeken 2024cited by 11position: middledoi
Plasma proteome profiling in giant cell arteritis.
2024cited by 5position: contributordoi
Rituximab versus azathioprine for maintenance of remission for patients with ANCA-associated vasculitis and relapsing disease: an international randomised controlled trial
Annals of the Rheumatic Diseases 2023cited by 113position: middledoi
Rituximab versus azathioprine for maintenance of remission for patients with ANCA-associated vasculitis and relapsing disease: an international randomised controlled trial.
2023cited by 83position: contributordoi
The Association Between Age at Diagnosis and Disease Characteristics and Damage in Patients With <scp>ANCA‐Associated</scp> Vasculitis
Arthritis & Rheumatology 2023cited by 25position: middledoi
Duration of Steroid Therapy and Temporal Artery Biopsy Positivity in Giant Cell Arteritis: A Retrospective Cohort Study.
2023cited by 3position: contributordoi
OP0102 IDENTIFICATION OF NEW RISK LOCI AND PATHWAYS INVOLVED IN GCA PATHOGENESIS BY A GENOME-WIDE STUDY
Annals of the Rheumatic Diseases 2023cited by 0position: middledoi
Safety, tolerability, and efficacy of pirfenidone in patients with rheumatoid arthritis-associated interstitial lung disease: a randomised, double-blind, placebo-controlled, phase 2 study
The Lancet Respiratory Medicine 2022cited by 196position: middledoi
Ocular manifestations of ANCA-associated vasculitis
Lara D. Veeken 2022cited by 34position: lastdoi
Neutrophil activation in patients with anti-neutrophil cytoplasmic autoantibody-associated vasculitis and large-vessel vasculitis
Arthritis Research & Therapy 2022cited by 30position: middledoi
Airway autoantibodies are determinants of asthma severity
European Respiratory Journal 2022cited by 27position: middledoi
Airway autoantibodies are determinants of asthma severity.
2022cited by 19position: contributordoi
Plasma exchange and glucocorticoids to delay death or end-stage renal disease in anti-neutrophil cytoplasm antibody-associated vasculitis: PEXIVAS non-inferiority factorial RCT.
2022cited by 10position: contributordoi
Self-Reported Data and Physician-Reported Data in Patients With Eosinophilic Granulomatosis With Polyangiitis: Comparative Analysis.
2022cited by 4position: contributordoi
Clinical Manifestations and Long‐Term Outcomes of Eosinophilic Granulomatosis With Polyangiitis in North America
ACR Open Rheumatology 2021cited by 55position: middledoi
Efficacy of leflunomide in the treatment of vasculitis
Clinical and Experimental Rheumatology 2021cited by 48position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Peter A. Merkel · University of the Sciences27 papers (2012–2025)Paul A. Monach · Boston University26 papers (2012–2024)Carol A. Langford · Cleveland Clinic26 papers (2012–2024)Curry L. Koening · University of Utah25 papers (2013–2024)Philip Seo · Johns Hopkins University25 papers (2012–2024)Simon Carette · Mount Sinai Hospital23 papers (2012–2021)David Cuthbertson · McMaster University22 papers (2012–2024)Carol A. McAlear · The University of Texas at Austin21 papers (2015–2024)Christian Pagnoux · University of Colorado Denver20 papers (2014–2024)Steven R. Ytterberg · Mayo Clinic20 papers (2012–2020)Larry W. Moreland · Queen Mary University of London19 papers (2015–2024)Kenneth J. Warrington · Mayo Clinic18 papers (2012–2025)Antoine G. Sreih · Bristol-Myers Squibb (United States)17 papers (2015–2024) · 16 papers (2019–2026)Ulrich Specks · Mayo Clinic16 papers (2013–2023)Gary S. Hoffman · McMaster University14 papers (2012–2019)Peter C. Grayson · National Institutes of Health8 papers (2012–2022)Mats Junek · AstraZeneca (Canada)7 papers (2021–2025)Kathleen Maksimowicz‐McKinnon · McMaster University7 papers (2012–2019)Tanaz A. Kermani · University of California, Los Angeles6 papers (2015–2024)